Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Wire Texas.
Press releases published on August 26, 2025
Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma
GlobeNewswire
·
August 26, 2025
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphoma showed 66% of Non-Hodgkin Lymphoma (NHL) patients achieving objective response rates, with 50% demonstrating complete response (CR) Favorable safety profile …
Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
GlobeNewswire
·
August 26, 2025
Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score U.S. regulatory submission …
EDAP Announces Letter of Intent for 36 Million Euro Credit Facility to Accelerate Growth and Strategic Expansion
GlobeNewswire
·
August 26, 2025
Funding to Support Continued Growth of Focal One® Robotic HIFU AUSTIN, Texas, August 26, 2025 - EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced execution of a letter of intent for …
Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
GlobeNewswire
·
August 26, 2025
BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the 2025 Cantor …
Syndax Announces Participation in September Investor Conferences
GlobeNewswire
·
August 26, 2025
NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of …
EyePoint Announces Participation at Upcoming Investor Conferences
GlobeNewswire
·
August 26, 2025
WATERTOWN, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced …
Voyager to Present at Upcoming Investor Conferences
GlobeNewswire
·
August 26, 2025
LEXINGTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following …
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
GlobeNewswire
·
August 26, 2025
WARREN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and …
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
GlobeNewswire
·
August 26, 2025
SAN MATEO, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management …
Teleflex to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
GlobeNewswire
·
August 26, 2025
WAYNE, Pa., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE: TFX) will be presenting at the Morgan Stanley 23rd Annual Global Healthcare Conference at the Sheraton New York Times Square, on Tuesday, September 9, 2025, at 3:20 p. …
Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors
GlobeNewswire
·
August 26, 2025
— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease — — Pro forma cash and cash equivalents, assuming …
Breaking the Sick Cycle: How Healthletic's First-Day Colostrum With 25% IgG Is Revolutionizing Natural Immune Defense
GlobeNewswire
·
August 26, 2025
New York, USA, Aug. 26, 2025 (GLOBE NEWSWIRE) -- In an era where the average adult loses 5-7 work days annually to illness and parents navigate an endless cycle of daycare bugs, a growing body of research points to bovine colostrum—specifically first-day …
Osivax Receives $19.5M BARDA Award to Advance Next-Generation Influenza Vaccine for Pandemic and Seasonal Preparedness
GlobeNewswire
·
August 26, 2025
Funding to accelerate development of Osivax’ broad-spectrum influenza A vaccine candidate, OVX836 Lyon, France and Liège, Belgium – August 26, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against …
Scenic Enters License and Research Agreement with Alnylam
GlobeNewswire
·
August 26, 2025
Amsterdam, the Netherlands, August 26, 2025 – Scenic Biotech, a pioneer in modifier therapies for severe diseases, today announced a license and research agreement with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) to leverage Scenic's Cell-Seq platform …
Er-Kim Announces Exclusive Agreement with CNX Therapeutics to Distribute Oncology Products Across CEE and Turkey
GlobeNewswire
·
August 26, 2025
WARSAW, Poland and LONDON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, today announced a distribution agreement with CNX Therapeutics to supply selected …
Life Biosciences Presents New Data at ARDD 2025 on the Company’s Partial Epigenetic Reprogramming Platform in Liver and Ocular Diseases
GlobeNewswire
·
August 26, 2025
ER-300 improves key biomarkers of liver health in an animal model of MASH These data, along with additional ER-100 preclinical data from a nonhuman primate model of NAION demonstrating clear restoration of methylation patterns with functional enrichment of …
Rakovina Therapeutics CSO Dr. Mads Daugaard Invited to Present at the 13th Tuscany Retreat on Cancer Research and Apoptosis
GlobeNewswire
·
August 26, 2025
VANCOUVER, British Columbia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, today announced that …
CancerVax Achieves Major Milestones and Files Foundational Patent Application
GlobeNewswire
·
August 26, 2025
Lehi, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah, August 26, 2025 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that uses the body’s immune system to treat cancer, today announced that it recently filed a …
PannTheraPi prepares plans to conduct its first Phase IIa clinical trial with PTI5803 in patients with resistant epilepsy and accelerate the development of its proprietary pipeline
GlobeNewswire
·
August 26, 2025
PannTheraPi prepares plans to conduct its first Phase IIa clinical trial with PTI5803 in patients with resistant epilepsy and accelerate the development of its proprietary pipeline Pre-submission file completed with French regulatory agency (ANSM) to …
PannTheraPi se prépare pour mener son premier essai clinique de phase IIa avec le PTI5803 chez des patients atteints d'épilepsie résistante et accélérer le développement de son portefeuille propriétaire
GlobeNewswire
·
August 26, 2025
PannTheraPi se prépare pour mener son premier essai clinique de phase IIa avec le PTI5803 chez des patients atteints d'épilepsie résistante et accélérer le développement de son portefeuille propriétaire Dossier de pré-soumission finalisé auprès de l'Agence …